Lipoprotein(a) Integrates Monocyte-Mediated Thrombosis and Inflammation in Atherosclerotic Cardiovascular Disease

This translational study compared monocyte biology and transcriptomic profiles between 64 ASCVD patients stratified by high (≥100 nmol/L) versus low Lp(a) levels, then mechanistically validated findings using purified Lp(a) added to isolated monocytes in vitro.

Despite similar hs-CRP and total monocyte counts between high- and low-Lp(a) patients, high-Lp(a) patients showed elevated circulating markers of vascular dysfunction (tissue factor, CCL28, IL-17D), CD14+ monocytes with increased tissue factor (TF) surface expression at baseline, and PBMC transcriptomes with 365 differentially expressed genes enriched for immune activation pathways. Under LPS stimulation, high-Lp(a) PBMCs showed amplified TF induction. Purified Lp(a) directly activated monocytes, inducing rapid cytokine secretion (IL-6, TNFα) and TF expression through TLR2 and NFκB signaling pathways.

The study defines a specific molecular mechanism — “immunothrombosis” — through which Lp(a) simultaneously amplifies inflammation and coagulation in circulating monocytes. This is mechanistically distinct from Lp(a)‘s lipid-driven atherogenesis and explains how Lp(a) contributes to plaque instability and thrombotic events beyond simply accelerating plaque formation.

The finding has implications for how we understand Lp(a)‘s clinical danger: it is not only a structural risk for atherosclerosis but an active driver of the inflammatory-thrombotic cascade that triggers acute events. Anti-Lp(a) therapy may benefit not just through preventing plaque growth, but by reducing the immunothrombotic activation that causes plaque rupture and ACS.

We rate the evidence strong for mechanistic clarity. A rigorous translational study establishing TLR2/NFκB-mediated monocyte activation as the immunothrombotic mechanism underlying Lp(a)-driven cardiovascular risk.